#6 - Predictive Oncology (NASDAQ:POAI)
Investing in biotechnology stocks is the definition of risk-reward. If you're willing to take that risk, oncology is one area to consider. It goes without saying that cancer remains one of the leading worldwide causes of death. And for all the advancements that have been made, the end goal remains elusive.
Can AI help? That’s the thesis for investing in Predictive Oncology, Inc. (NASDAQ: POAI). The company is using AI to “change the landscape of oncology drug discovery.” Specifically, the company adds machine learning to its own processes and expertise to determine which drug compounds may have the highest likelihood of success with different tumor types in specific patients.
The company has been increasing revenue by 27% over the last five years. But, here’s where the risk comes in. Earlier this year, the company issued a 1-for-20 reverse stock split. Management says the move was only taken to ensure compliance with NASDAQ requirements. That may be true and if you can stomach that, this is a penny stock that could be a big winner in years to come.
About Predictive Oncology
Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Read More - Current Price
- $1.19
- Consensus Rating
- Hold
- Ratings Breakdown
- 0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $3.00 (152.1% Upside)
